High Content Screening (HCS) Market is poised to reach a valuation of US$ 1.5 billion by the end of 2021

The increasing demand for cell visualization and quantification using advance technique has been enabling growth in the global high content market. As per a study by Future Market Insights (FMI), driven by rising application in pharmaceutical and biotech companies, the market is poised to reach a valuation of US$ 1.5 Bn by the end of 2021. As per the study, the pharmaceutical and the healthcare sector will account for over 31% of demand registered in the market in 2021.

Gain complete access to the report @ https://www.futuremarketinsights.com/reports/high-content-screening-market

High content screening is adopted for drug discovery and development. Increasing research in search of the novel drug candidate and target identification & validation is expected to propel the adoption of high content screening over the forecast years. Besides this, continuous focus on manufacturing high quality and technologically advanced cell imaging system is expected to accelerate demand over the course of the forecast period.

However, due to COVID 19 outbreak, the research and development activities were hampered immensely. This is expected to have a negative impact on the market. Nonetheless, increasing investments by key manufacturers in the development of advanced cell imaging product is expected to boost the market in the coming years.

Prominent Players:

• Thermo Fisher Scientific Inc.
• Becton, Dickinson and Company
• GE Healthcare
• Olympus Corporation
• PerkinElmer Inc.
• Sysmex Corporation
• Merck KGaA
• Danaher Corporation
• Yokogawa Electric Corporation

To remain ‘ahead’ of your competitors, request for a sample - https://www.futuremarketinsights.com/reports/sample/rep-gb-426

Key Takeaways of High Content Screening Market Study

• The high content screening market will rise at register a little below 5% y-o-y growth in 2021, following a brief period of restrictions amid COVID-19

• Presence of a sophisticated healthcare and pharmaceutical infrastructure is enabling the U.S. market account for over 90% of sales in North America

• The U.K. will register an impressive 7.2% y-o-y growth in 2021 driven by increasing focus on research and development activities in the pharmaceutical sector

• Demand registered in Germany and France is expected to rise significantly within Europe
• Favorable government policies will support expansion in Japan, followed by China

“Demand for novel technologies for cell analysis and drug discovery is expected to improve the manufacturing speed, throughput, and reliability. This is expected to create growth opportunities for market players,” Says the FMI Analyst.

Who is winning?

The key manufacturers in the high content screening market are involved in several partnerships and collaboration to develop new cell imaging technology. The leading manufacturers are also making their business strategies by making collaborations with international laboratories and research institutes to develop new imaging technologies.

For instance, In December 2019, Leica Microsystems make a collaboration agreement with the European Molecular Biology Laboratory (EMBL) to develop new imaging technologies applicable in life science. With this agreement EMBL and Leica promoting new imaging technologies for cell imaging.

Valuable Insights into High Content Screening Market Study

Future Market Insights offers actionable insights and a unique perspective on the high content screening market in its latest study, presenting historical demand assessment from 2016 – 2020 and projections from 2021–2031 based on product (cell imaging & analysis, consumables, Software's, services), industry (pharmaceutical & healthcare, biotechnology, educational institutions, independent CRO, government organizations and others), and by application (primary & secondary screening, target identification & validation, toxicity studies, compound profiling and others) in seven key regions.

Get a Customized Scope to Match Your Need Ask an Expert- https://www.futuremarketinsights.com/ask-question/rep-gb-426

High-Content-Screening Market by Category

Product Type

• Cell Imaging & Analysis
o HCS Instruments
 High-End HCS
 Mid End HCS
 Low-End HCS
o Flow Cytometers

• Consumables

o Microplates
o Reagents & Assay Kits
o Other Consumables
• Softwares
• Services

Industry

• Pharmaceutical & Healthcare
• Biotechnology
• Educational Institutions
• Independent CRO
• Government Organizations
• Others

Application

• Primary & Secondary Screening
• Target Identification & Validation
• Toxicity Studies
• Compound Profiling
• Others

For critical insights, request for PDF Brochure: https://www.futuremarketinsights.com/reports/brochure/rep-gb-426

Region

• North America
• Latin America
• Europe
• East Asia
• South Asia
• Oceania
• Middle East and Africa (MEA)

Contact:
Future Market Insights,
1602-6 Jumeirah Bay X2 Tower,
Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
For Sales Enquiries: sales@futuremarketinsights.com
For Media Enquiries: press@futuremarketinsights.com
Website: https://www.futuremarketinsights.com/

About Future Market Insights (FMI)
Future Market Insights (FMI) is a leading provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in Dubai, and has delivery centers in the UK, U.S. and India. FMI's latest market research reports and industry analysis help businesses navigate challenges and make critical decisions with confidence and clarity amidst breakneck competition. Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. A team of expert-led analysts at FMI continuously tracks emerging trends and events in a broad range of industries to ensure that our clients prepare for the evolving needs of their consumers.

This release was published on openPR.